Symptom Based Treatment of Neuropathic Pain

Symptom-Based Treatment for Neuropathic Pain in Spinal Cord Injured Patients, Randomized Clinical Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02180880

Enrollment

Registered

2014-07-03

Start date

2012-11-30

Completion date

2014-08-31

Last updated

2014-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuralgia, Spinal Cord Injury

Keywords

Neuralgia, Spinal cord, Oxcarbazepine, Pregabalin, Drug therapy, Algorithms

Brief summary

1\. Neuropathic pain in spinal cord injured patients 1. Inclusion criteria * pain intensity, visual analogue scale \> 3 * a LANSS (Leeds assessment of neuropathic symptoms and signs) score of 12 and above * aged ≥20 2. Method * Stop pain medications * Test oxcarbazepine (150mg twice daily) and pregabalin (150mg twice daily) * Check pain intensity (VAS score) with Baron's classification

Detailed description

In the present study, pharmacologic treatment included pregabalin and oxcarbazepine. Stop medications such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), tramadol and anti-spastic drugs (baclofen, tizanidine) and other medications known to have effect on pain and the central nervous system prior to the study for at least 3 days. 1. Pain intensity (VAS score) 1. 4 spontaneous characters * electric * burning * pricking * numbness 2. evoked pain * allodynia * heat hyperalgesia * pressure hyperalgesia 2. Location of neuropathic pain 1. neuropathic pain at level of spinal cord injury 2. neuropathic pain below level of spinal cord injury 2\. Side effects

Interventions

DRUGPregabalin and Oxcarbazepine

Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day. Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* aged than 20 years * Neuropathic pain symptoms : LANSS (Leeds assessment of neuropathic symptoms and signs) score of 12 and above * Visual analogue scale score of 3 and above

Exclusion criteria

* No pregnancy * systemic disease * psychiatric disease

Design outcomes

Primary

Measure	Time frame	Description
Symptom based treatment of neuropathic pain	2 week later	Pain intensity using Visual analogue scale (0\ 100)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026